Everolimus in Combination with Crizotinib Synergistically Inhibits the Growth of ALK-Positive Anaplastic Large Cell Lymphoma Cells

被引：1
|
作者：
Xu, Wendan [1 ]
Kim, Ji-Won [2 ]
Lee, Junglim [3 ]
Kim, Hyo Jung [4 ]
Yoon, Hwi-Joong [5 ]
Yoon, Sung-Soo [2 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[3] Daegu Fatima Hosp, Taegu, South Korea
[4] Hallym Univ, Coll Med, Anyang, South Korea
[5] Kyung Hee Univ Hosp, Seoul, South Korea
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.4488.4488
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Synergistic cytotoxicity of everolimus in combination with crizotinib in ALK-positive anaplastic large cell lymphoma cells
    Kim, Ji-Won
    Xu, Wendan
    Yoon, Sung-Soo
    CANCER RESEARCH, 2015, 75
  • [2] Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase - Positive Anaplastic Large Cell Lymphoma
    Xu, Wendan
    Kim, Ji-Won
    Jung, Woo June
    Koh, Youngil
    Yoon, Sung-Soo
    CANCER RESEARCH AND TREATMENT, 2018, 50 (02): : 599 - 613
  • [3] Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition
    Kim, Dongchan
    Koh, Youngil
    Yoon, Sung-Soo
    ANTICANCER RESEARCH, 2020, 40 (03) : 1395 - 1403
  • [4] Anaplastic large cell lymphoma, ALK-positive
    Ferreri, Andres J. M.
    Govi, Silvia
    Pileri, Stefano A.
    Savage, Kerry J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (02) : 293 - 302
  • [5] Refractory or relapsed ALK-positive anaplastic T large cell lymphoma treated with crizotinib
    Miaomiao, L.
    Zhang, M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1758 - 1758
  • [6] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Ganesan, Prasanth
    Joshua, Thanda
    Sundersingh, Shirley
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 353 - 354
  • [7] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Prasanth Ganesan
    Thanda Joshua
    Shirley Sundersingh
    Tenali Gnana Sagar
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 353 - 354
  • [8] Immune response to ALK in ALK-positive anaplastic large cell lymphoma
    Woessmann, W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 23 - 24
  • [9] ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern
    Yu, Guohua
    Gao, Zifen
    Huang, Xin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (12): : 9086 - 9089
  • [10] Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics
    Meurillon, Roxane
    Leruste, Amaury
    BULLETIN DU CANCER, 2023, 110 (03) : 250 - 251
12345